GSK ratings under pressure with Tesaro buy, states Moody's
Moody’s has slapped a negative outlook on the UK’s GlaxoSmithKline, after the pharmaceuticals company said it planned a debt funded $5.1bn deal for US oncology company Tesaro.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: